Future Industry Investment Fund managed by SDIC Fund Management Company (“SDIC Fund”) and Sherpa Healthcare Partners recently co-led and completed a Series B financing of a leading local biopharmaceutical R&D company, EpimAb Biotherapeutics (“EpimAb”).

SDIC Fund is a professional private equity fund manager operated independently in market-oriented mode. As one of the largest private equity managers in China, SDIC Fund currently manages approximately RMB 60 billion of capital from diversified LPs, including financial institutions, Social Security Fund, private enterprises and stated-owned enterprises. Future Industry Investment Fund, approved by the State Council, jointly headed by the National Development and Reform Commission, Ministry of Finance, and the Ministry of Industry and Information Technology, is established through joint investment by the central government fund and social capital, which currently owns RMB 20 billion, mainly focusing on high-end medical equipment and medicines, intelligent manufacturing, industrial robots, new energy vehicles, new materials, rail transportation equipment, modern agricultural machinery, high-end ship and ocean engineering equipment and other areas.

Sherpa Healthcare Partners is built by an exceptionally experienced investors, focused on the investment and cultivation of the Pharmaceutical and Biotech industry. Sherpa specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where the team have established robust portfolio sources, lasting value-adding collaborations and relationships, as well as, matured all-cycle services with key resources. The core team has been working together for a few fund cycles and key members all have more than 15 years of healthcare investment operation and management experience, with aligned values, deep mutual trust, and critically complimentary expertise.

EpimAb Biotherapeutics is an innovative and international biopharmaceutical R&D company with a proprietary unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties. Its first product candidate EMB-01 is currently being investigated in a clinical Phase I/II trial in the USA and China. With this platform, EpimAb is creating a pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients. EpimAb is also committed to diversifying its pipeline through selective licensing of its platform to partners worldwide. EpimAb has established a R&D center in Shanghai and a pilot experiment base in Suzhou.

The legal service provided by Cathay Associates Kejie in this transaction mainly includes legal due diligence, transaction documents review, negotiation, and closing.

The Cathay Associates Kejie team advising this transaction was led by partner Zhang Fang.